---
title: "Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293133843.md"
description: "On July 17, 2026, San Carlos based Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) revealed the approval of granting inducement stock options on July 16, 2026. The options cover a total of 139,930 shares of the company's common stock and have been offered to seventeen fresh, non-executive employees. Iovance focuses on developing innovative polyclonal tumor infiltrating lymphocyte (\"TIL\") therapies for cancer patients."
datetime: "2026-07-19T21:31:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293133843.md)
  - [en](https://longbridge.com/en/news/293133843.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293133843.md)
---

# Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

On July 17, 2026, San Carlos based Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) revealed the approval of granting inducement stock options on July 16, 2026. The options cover a total of 139,930 shares of the company's common stock and have been offered to seventeen fresh, non-executive employees. Iovance focuses on developing innovative polyclonal tumor infiltrating lymphocyte ("TIL") therapies for cancer patients.

### Related Stocks

- [IOVA.US](https://longbridge.com/en/quote/IOVA.US.md)

## Related News & Research

- [Is Iovance Biotherapeutics (IOVA) Undervalued On Q2 Earnings And Reaffirmed Guidance?](https://longbridge.com/en/news/295324260.md)
- [Iovance publishes corporate presentation highlighting Amtagvi TIL therapy rollout and pipeline expansion in solid tumors](https://longbridge.com/en/news/295105932.md)
- [Should Elevance’s Data Partnership And Cancer Care Model Results Require Action From Elevance Health (ELV) Investors?](https://longbridge.com/en/news/295821569.md)
- [Liminatus Pharma moves Nasdaq listing to Capital Market tier](https://longbridge.com/en/news/295788272.md)
- [Short Interest in Entera Bio Ltd. (NASDAQ:ENTX) Increases By 286.7%](https://longbridge.com/en/news/295783160.md)